Want to see CALC full AI Analyst Report?
Top Page
CalciMedica
(NASDAQ:CALC)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.62
▼(-18.95% Downside)
Action:Reiterated
Date:08/19/26
The score is held down primarily by weak financial performance (no revenue, sizable losses, and significant ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide some support via extended funding runway and favorable FDA safety feedback, but dilution risk remains elevated and valuation signals are constrained by negative earnings.
Positive Factors
Improved Balance Sheet
No debt and positive equity reduce near-term leverage risk and provide a cleaner financial base for development activities. This improvement gives CalciMedica greater flexibility while it seeks clinical milestones and additional funding.
Negative Factors
Pre-Revenue Business Model
CalciMedica has no commercial product revenue to fund operations, while substantial losses continue. Until a program reaches commercialization or generates partnership income, the company remains dependent on clinical execution and external capital to sustain its business.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
No debt and positive equity reduce near-term leverage risk and provide a cleaner financial base for development activities. This improvement gives CalciMedica greater flexibility while it seeks clinical milestones and additional funding.
Read all positive factors
CalciMedica (CALC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.62M
Dividend YieldN/A
Average Volume (3M)71.94K
Price to Earnings (P/E)―
Beta (1Y)-0.39
Revenue GrowthN/A
EPS Growth15.37%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.38
Shares Outstanding34,141,460
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.74
Revenue Forecast (FY)N/A
CalciMedica Business Overview & Revenue Model
Company Description
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approac...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, CalciMedica does not have publicly established recurring product revenue from commercialized drugs. Its funding and cash inflows are therefore primarily driven by external financing and, when applicab...
CalciMedica Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | -519.00K |
| EBITDA | -19.91M | -28.09M | -13.64M | -34.19M | -7.64M | -35.30M |
| Net Income | -21.24M | -29.56M | -13.70M | -34.36M | -7.82M | -35.82M |
Balance Sheet | ||||||
| Total Assets | 19.50M | 13.59M | 19.79M | 12.19M | 3.35M | 69.09M |
| Cash, Cash Equivalents and Short-Term Investments | 18.62M | 13.02M | 18.67M | 11.24M | 1.33M | 63.67M |
| Total Debt | 0.00 | 9.70M | 0.00 | 0.00 | 5.36M | 0.00 |
| Total Liabilities | 13.99M | 20.23M | 5.38M | 4.03M | 12.58M | 4.07M |
| Stockholders Equity | 5.51M | -6.64M | 14.41M | 8.16M | -9.23M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -19.12M | -21.21M | -21.15M | -25.81M | -11.76M | -31.99M |
| Operating Cash Flow | -19.11M | -21.18M | -21.15M | -25.73M | -11.76M | -31.50M |
| Investing Cash Flow | 12.20M | 9.55M | -4.42M | 8.88M | -4.00K | 10.75M |
| Financing Cash Flow | 19.60M | 15.21M | 27.97M | 20.90M | 8.48M | 695.00K |
CalciMedica Technical Analysis
Negative
0.76
Price Trends
0.80
Negative
0.73
Negative
1.89
Negative
Market Momentum
-0.04
Positive
42.68
Neutral
21.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CALC, the sentiment is Negative. The current price of 0.76 is above the 20-day moving average (MA) of 0.72, below the 50-day MA of 0.80, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 42.68 is Neutral, neither overbought nor oversold. The STOCH value of 21.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CALC.
CalciMedica Risk Analysis
CalciMedica disclosed 71 risk factors in its most recent earnings report. CalciMedica reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CalciMedica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $33.24M | -1.60 | -456.35% | ― | ― | 9.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $12.34M | -0.34 | -346.03% | ― | ― | 30.16% | |
43 Neutral | $22.62M | -0.48 | 4092.98% | ― | ― | 15.37% | |
43 Neutral | $14.70M | -0.30 | -217.27% | ― | ― | -19.08% | |
41 Neutral | $13.39M | -0.24 | -503.79% | ― | ― | 80.28% |
* Healthcare Sector Average
CALC
CalciMedica
0.64
-2.14
-77.05%
PDSB
PDS Biotechnology
0.21
-0.96
-82.22%
SKYE
Skye Bioscience
0.36
-2.97
-89.22%
LTRN
Lantern Pharma
2.52
-1.94
-43.50%
SNTI
Senti Biosciences
0.43
-1.17
-73.13%
CalciMedica Corporate Events
Executive/Board Changes
CalciMedica Announces Board Expansion and Leadership Transition
Neutral
Jul 7, 2026
On July 2, 2026, CalciMedica’s board of directors expanded from seven to eight seats and appointed Evgeny Zaytsev, M.D., Ph.D., as a Class I director, with his term running until the 2027 annual meeting of stockholders. Zaytsev’s appoi...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
CalciMedica Advances Auxora After Favorable FDA Safety Review
Positive
Jun 24, 2026
On June 23, 2026, CalciMedica entered into a securities purchase agreement for a private placement of 18,673,429 units of stock and warrants with institutional and accredited investors, including several insiders, at prices around $0.80 per unit. ...
Business Operations and StrategyPrivate Placements and Financing
CalciMedica Amends Loan, Issues New Equity Warrants
Positive
Jun 24, 2026
On June 23, 2026, CalciMedica amended its existing $10 million loan and security agreement with Avenue Venture Opportunities Fund II, extending the interest-only period by one year to September 30, 2027 and pushing the loan’s maturity to Sep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.